Skip to main content

The Predictive Value of Lp(a) for Adverse Cardiovascular Event in ACS Patients With an Achieved LDL-C Target at Follow Up After PCI

Abstract

Low-density lipoprotein cholesterol (LDL-C) is a traditional and important risk factor for atherosclerotic cardiovascular disease (CVD). Recently, lipoprotein (a) (lp(a)) attracts considerable attention as a residual risk factor for CVD. However, the roles of lp(a) in acute coronary syndrome (ACS) patients with well-controlled LDL-C (≤1.8mmol/L) after percutaneous coronary intervention (PCI) remain unclear. Current study results demonstrated that occurrence of major adverse cardiovascular events (MACE) and recurrent myocardial infarction (MI) increased with the Lp(a) increasing in patients with LDL-C≤1.8mmol/L at 1-month follow-up. In relatively low-risk patients presented with ACS and underwent PCI (LDL-C ≤1.8mmol/L at 1-month follow-up), lp(a) is still independently related to adverse prognosis. Further researches of targeted therapy against lp(a) are warranted.

This is a preview of subscription content, access via your institution.

Fig. 1.
Fig. 2.
Fig. 3.

References

  1. 1.

    Hu, X., Yang, X., Li, X., Luo, D., Zhou, Y., & Dong, H. (2020). Lipoprotein (a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: A hospital-based cross-sectional study. Lipids in Health and Disease, 19(1), 173.

    CAS  Article  Google Scholar 

  2. 2.

    Cai, A., Li, L., Zhang, Y., Mo, Y., Mai, W., & Zhou, Y. (2013). Lipoprotein(a): A promising marker for residual cardiovascular risk assessment. Disease Markers, 35(5), 551–559.

    Article  Google Scholar 

  3. 3.

    Mach, F., Baigent, C., Catapano, A., Koskinas, K., Casula, M., Badimon, L., et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188.

    Article  Google Scholar 

  4. 4.

    Catapano, A., Graham, I., De Backer, G., Wiklund, O., Chapman, M., Drexel, H., et al. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37(39), 2999–3058.

    Article  Google Scholar 

  5. 5.

    Campbell, C., Rivera, J., & Blumenthal, R. (2007). Residual risk in statin-treated patients: Future therapeutic options. Current Cardiology Reports, 9(6), 499–505.

    Article  Google Scholar 

  6. 6.

    Erqou, S., Kaptoge, S., Perry, P., Di Angelantonio, E., Thompson, A., White, I., et al. (2009). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 302(4), 412–423.

    CAS  Article  Google Scholar 

  7. 7.

    Nicholls, S., Tang, W., Scoffone, H., Brennan, D., Hartiala, J., Allayee, H., et al. (2010). Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. Journal of Lipid Research, 51(10), 3055–3061.

    CAS  Article  Google Scholar 

  8. 8.

    Nielsen, L., Grønholdt, M., Schroeder, T., Stender, S., & Nordestgaard, B. (1997). In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arteriosclerosis, Thrombosis, and Vascular Biology, 17(5), 905–911.

    CAS  Article  Google Scholar 

  9. 9.

    Boffa, M., Marcovina, S., & Koschinsky, M. (2004). Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models. Clinical Biochemistry, 37(5), 333–343.

    CAS  Article  Google Scholar 

  10. 10.

    Poon, M., Zhang, X., Dunsky, K., Taubman, M., & Harpel, P. (1997). Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation, 96(8), 2514–2519.

    CAS  Article  Google Scholar 

  11. 11.

    Nielsen, L., Juul, K., & Nordestgaard, B. (1998). Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: In vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 18(4), 641–649.

    CAS  Article  Google Scholar 

  12. 12.

    Bennet, A., Di Angelantonio, E., Erqou, S., Eiriksdottir, G., Sigurdsson, G., Woodward, M., et al. (2008). Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data. Archives of Internal Medicine, 168(6), 598–608.

    CAS  Article  Google Scholar 

  13. 13.

    Jørgensen, A., Frikke-Schmidt, R., West, A., Grande, P., Nordestgaard, B., & Tybjærg-Hansen, A. (2013). Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. European Heart Journal, 34(24), 1826–1833.

    Article  Google Scholar 

  14. 14.

    Suk Danik, J., Rifai, N., Buring, J., & Ridker, P. (2006). Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA, 296(11), 1363–1370.

    CAS  Article  Google Scholar 

  15. 15.

    Liu, H., Cao, Y., Jin, J., Zhang, H., Hua, Q., Li, Y., et al. (2020). Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart (British Cardiac Society)., 106(16), 1228–1235.

    Google Scholar 

  16. 16.

    Schwartz, G., Ballantyne, C., Barter, P., Kallend, D., Leiter, L., Leitersdorf, E., et al. (2018). Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiology, 3(2), 164–168.

    Article  Google Scholar 

  17. 17.

    Levine, G., Bates, E., Bittl, J., Brindis, R., Fihn, S., Fleisher, L., et al. (2016). 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation, 134(10), e123-55.

  18. 18.

    Li, Z., Li, G., Zhou, Y., Chen, Z., Yang, J., Zhang, Y., et al. (2013). Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention. Lipids in health and disease, 12(127).

  19. 19.

    Nestel, P., Barnes, E., Tonkin, A., Simes, J., Fournier, M., White, H., et al. (2013). Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(12), 2902–2908.

    CAS  Article  Google Scholar 

  20. 20.

    O'Donoghue, M., Morrow, D., Tsimikas, S., Sloan, S., Ren, A., Hoffman, E., et al. (2014). Lipoprotein(a) for risk assessment in patients with established coronary artery disease. Journal of the American College of Cardiology, 63(6), 520–527.

    CAS  Article  Google Scholar 

  21. 21.

    Holmer, S. R., Hengstenberg, C., Kraft, H. G., Mayer, B., Pöll, M., Kürzinger, S., et al. (2003). Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation, 107(5), 696–701.

    Article  Google Scholar 

  22. 22.

    Giugliano, R., Pedersen, T., Park, J., De Ferrari, G., Gaciong, Z., Ceska, R., et al. (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet (London, England), 390(10106), 1962–1971.

    CAS  Article  Google Scholar 

  23. 23.

    Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Blom, D., Seidah, N. G., et al. (2016). PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Journal of Lipid Research, 57(6), 1086–1096.

    CAS  Article  Google Scholar 

  24. 24.

    Cai, A., Li, L., Zhang, Y., Mo, Y., Li, Z., Mai, W., et al. (2013). Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. Disease Markers, 35(6), 857–862.

    Article  Google Scholar 

  25. 25.

    Liu, H. H., Cao, Y. X., Jin, J. L., Zhang, H. W., Hua, Q., Li, Y. F., et al. (2020). Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. Journal of the American Heart Association, 9(3), e014581.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Yidu Cloud Technology Co., Ltd for their assistance in data searching, extraction, and processing.

Funding

This study was funded by Liaoning Province Natural Science Foundation ((20180550892) to Dr. Yin and (2019-ZD-0635) to Dr. Ren).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Yunlong Xia or Da Yin.

Ethics declarations

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Conflict of Interest

All the authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Associate Editor Craig M. Stolen oversaw the review of this article

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ren, Y., Pan, W., Li, X. et al. The Predictive Value of Lp(a) for Adverse Cardiovascular Event in ACS Patients With an Achieved LDL-C Target at Follow Up After PCI. J. of Cardiovasc. Trans. Res. (2021). https://doi.org/10.1007/s12265-021-10148-2

Download citation

Keywords

  • Low-density lipoprotein cholesterol
  • Lipoprotein(a)
  • Major adverse cardiovascular events